RTP-based Incyclix Bio LLC has secured a $11.25 million extension to its Series B financing. The additional funding will help Incyclix Bio advance its first-in-human clinical trial of INX-315, an oral inhibitor of cyclin-dependent kinase 2 (CDK2) being developed to treat advanced and resistant cancer. Drawing on its deep understanding of key structural features within CDK2’s drug-binding site, Incyclix Bio developed a potent and selective CDK2 inhibitor. “Our ability to grow and attract strong investors to advance INX-315 has been driven by the supportive environment of RTP,” said Roberts. “We’re proud to be part of this thriving life science community fueling innovation and building a brighter future for patients.”